

## **CDMO Sector Perspectives on OMUFA Reauthorization**

Cornell Stamoran, Ph.D. September 28, 2023

**PHARMA & BIOPHARMA** OUTSOURCING ASSOCIATION The Pharma-Biopharma Outsourcing Association (PBOA), founded in 2014, is a nonprofit trade association dedicated to advancing the regulatory, legislative, and general business interests of *Contract Development and Manufacturing Organizations (CDMOs)* and other contract service providers.

Today, PBOA has 50+ member companies, along with 23 affiliate members, who provide the technologies and services that help the pharma, biopharma, and consumer health industry develop, manufacture, and package drugs, vaccines, OTC products, and other treatments safely, reliably, and cost effectively

# CDMOs are central to success of the biopharma and consumer health industry


- We enabled development of >80% of NMEs approved by the FDA and EMA over last decade
- We produced >55% of NMEs approved since 2017 including COVID-19 vaccines and treatments authorized under EUAs
- Overall, we **produce 2 of every 5 doses** of drugs, vaccines, and OTC products dispensed in western markets
- We play a **critical role in early pharma innovation** by enabling emerging biopharmas ~75% of active pipeline
- We supply ANDA-/monograph-based OTCs, nutritionals
- We employ ~35,000 across ~170 US facilities
- Our FDA inspection Form 483 issuance rates are comparable<sup>1</sup> with branded company captive facilities
- We produce **more than a dozen modalities across all routes** of administration (e.g. small molecules, proteins, gene/cell)
- We do not own, set prices for, or distribute drugs<sup>2</sup>

Note: all statistics represent PBOA members only

- 1 Versus captive sterile and non-sterile facilities on average, source: Redica FDAZilla
- 2 Certain members are divisions of filing-holders or own NDA/BLA/ANDAs



#### **PBOA members support global drug development & supply**



Not shown: Facilities in middle east, Australia, Egypt, South Africa, Singapore, and Puerto Rico

- More than **300 operating facilities** around the globe, plus other offices and labs
- Finished dose facilities cover all dose formats, including ~80 injectable fill/finish
- API facilities include chemicals (50), proteins (40), and gene and cell (24)
- ~85% of commercial sites registered w/ FDA, EMA, or MHRA or pending such
- Global employment ~50,000+
- A site may be the **sole source** of a product, a sole external source, or part of a multisite sourcing network



### **PBOA Members Impacted by Most User Fee Programs**

- PBOA members are currently involved in most of FDA's User Fee programs: PDUFA, GDUFA, BSUFA, ADUFA, MDUFA, OMUFA
- Key design principles for user fee-driven programs, including enhancements thereto:
  - The party who receives the economic benefit should pay the fees, both for the program and any enhancements thereto
  - The fee should fully recover the **actual or best estimate of cost** of services provided, unless there's a public policy reason to do otherwise (e.g. effective time reporting, etc.)
  - Ability to implement; available data/IT systems to effectively support; auditability/transparency
- Real downside impact for PBOA members of mis-aligned fees and value: layoffs; reduced capacity available (supply disruption/shortage risk?); reduced ability to invest in innovation, capacity, new jobs



### **PBOA Perspectives on OMUFA Reauthorization**

- PBOA continues to support OMUFA's fundamental goals and approach, and recognizes FDA's progress despite the impacts of the pandemic
- The pandemic and resulting pullback in consumer spending has impacted OTC and nutritional supplement demand – causing a contraction of available CDMO supply via facility layoffs/closures, insourcing, geopolitical supply chain issues
- As program focus turns to OMORs, we will seek transparency of OMOR efforts and outcomes, as we've seen with other maturing UFA programs
- Effectively redeploy and fully leverage OMUFA-funded resources to support evolving program, before seeking to expand staffing
- Align payment of negotiated increases in fees to those parties receiving the economic benefits therefrom



#### **PBOA Contacts**



PBOA Gil Roth President <u>Gil.roth@pharma-bio.org</u> 201.788.7994



**Catalent, Inc**. Cornell Stamoran, PhD VP, Strategy & Govt Affairs <u>Cornell.stamoran@catalent.com</u> 908.313.0643

**PBOA Trustee** 

